CoChat

Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis

Open access
Tarry-Adkins, Jane L., Aiken, Catherine E., Ozanne, Susan E. · 2020 · PLoS Medicine

The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Fetal growth in gestational diabetes mellitus (GDM) is directly linked to maternal glycaemic control; however, this relationship may be altered by oral anti-hyperglycaemic agents. Unlike insulin, such drugs cross the placenta and may thus have independent effects on fetal or placental tissues. We investigated the association between GDM treatment and fetal, neonatal, and childhood growth. METHODS AND FINDINGS: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and Cochrane databases were systematically searched (inception to 12 February 2020). Outcomes of GDM-affected pregnancies randomised to treatment with metformin, glyburide, or insulin were included. Studies including preexisting diabetes or nondiabetic women were excluded. Two reviewers independently assessed eligibility and risk of bias, with conflicts resolved by a third reviewer. Maternal outcome measures were glycaemic control, weight gain, and treatment failure. Offspring anthropometric parameters included fetal, neonatal, and childhood weight and body composition data. Thirty-three studies (n = 4,944), from geographical locations including Europe, North Africa, the Middle East, Asia, Australia/New Zealand, and the United States/Latin America, met eligibility criteria. Twenty-two studies (n = 2,801) randomised women to metformin versus insulin, 8 studies (n = 1,722) to glyburide versus insulin, and 3 studies (n = 421) to metformin versus glyburide. Eleven studies (n = 2,204) reported maternal outcomes. No differences in fasting blood glucose (FBS), random blood glucose (RBS), or glycated haemoglobin (HbA1c) were reported. No studies reported fetal growth parameters. Thirty-three studies (n = 4,733) reported birth weight. Glyburide-exposed neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10-106.31, p = 0.02) with increased risk of macrosomia (odds ratio [OR] 1.38, 95% CI 1.01-1.89, p = 0.04) versus neonates of insulin-treated mothers. Metformin-exposed neonates were born lighter (-73.92 g, 95% CI -114.79 to -33.06 g, p < 0.001) with reduced risk of macrosomia (OR 0.60, 95% CI 0.45-0.79, p < 0.001) than insulin-exposed neonates. Metformin-exposed neonates were born lighter (-191.73 g, 95% CI -288.01 to -94.74, p < 0.001) with a nonsignificant reduction in macrosomia risk (OR 0.32, 95% CI 0.08-1.19, I2 = 0%, p = 0.09) versus glyburide-exposed neonates. Glyburide-exposed neonates had a nonsignificant increase in total fat mass (103.2 g, 95% CI -3.91 to 210.31, p = 0.06) and increased abdominal (0.90 cm, 95% CI 0.03-1.77, p = 0.04) and chest circumferences (0.80 cm, 95% CI 0.07-1.53, p = 0.03) versus insulin-exposed neonates. Metformin-exposed neonates had decreased ponderal index (-0.13 kg/m3, 95% CI -0.26 to -0.00, p = 0.04) and reduced head (-0.21, 95% CI -0.39 to -0.03, p = 0.03) and chest circumferences (-0.34 cm, 95% CI -0.62 to -0.05, p = 0.02) versus the insulin-treated group. Metformin-exposed neonates had decreased ponderal index (-0.09 kg/m3, 95% CI -0.17 to -0.01, p = 0.03) versus glyburide-exposed neonates. Study limitations include heterogeneity in dosing, heterogeneity in GDM diagnostic criteria, and few studies reporting longitudinal growth outcomes. CONCLUSIONS: Maternal randomisation to glyburide resulted in heavier neonates with a propensity to increased adiposity versus insulin- or metformin-exposed groups. Metformin-exposed neonates were lighter with reduced lean mass versus insulin- or glyburide-exposed groups, independent of maternal glycaemic control. Oral anti-hyperglycaemics cross the placenta, so effects on fetal anthropometry could result from direct actions on the fetus and/or placenta. We highlight a need for further studies examining the effects of intrauterine exposure to antidiabetic agents on longitudinal growth, and the importance of monitoring fetal growth and maternal glycaemic control when treating GDM. This review protocol was registered with PROSPERO (CRD42019134664/CRD42018117503).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1003126

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 PRISMA flow diagram (metformin versus insulin, glyburide versus insulin, glyburide versus metformin). PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Fig 1 PRISMA flow diagram (metformin versus insulin, glyburide versus insulin, glyburide versus metformin). PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.CC BY · PubMed Central
Fig 2 Total gestational weight gain for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as mean difference and fixed effects model, except metformin versus insulin (expressed as random effects model). All comparisons 95% CI. CI, confidence interval.
Fig 2 Total gestational weight gain for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as mean difference and fixed effects model, except metformin versus insulin (expressed as random effects model). All comparisons 95% CI. CI, confidence interval.CC BY · PubMed Central
Fig 3 Birth weight for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as mean difference (fixed effects model) and 95% CI. CI, confidence interval.
Fig 3 Birth weight for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as mean difference (fixed effects model) and 95% CI. CI, confidence interval.CC BY · PubMed Central
Fig 4 Macrosomia for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as mean difference (random effects model). Expressed as OR (fixed effects model) and 95% CI. CI, confidence interval; OR, odds ratio.
Fig 4 Macrosomia for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as mean difference (random effects model). Expressed as OR (fixed effects model) and 95% CI. CI, confidence interval; OR, odds ratio.CC BY · PubMed Central
Fig 5 LGA for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as OR (fixed effects model) with the exception of the glyburide versus insulin comparison (random effect model). All comparisons 95% CI. CI, confidence interval; LGA, large for gestational age; OR, odds ratio.
Fig 5 LGA for (A) glyburide versus insulin, (B) metformin versus insulin, and (C) metformin versus glyburide comparisons. Expressed as OR (fixed effects model) with the exception of the glyburide versus insulin comparison (random effect model). All comparisons 95% CI. CI, confidence interval; LGA, large for gestational age; OR, odds ratio.CC BY · PubMed Central
Fig 6 Summary diagram of the mechanisms of action of GDM intervention on mother and baby. GDM, gestational diabetes mellitus.
Fig 6 Summary diagram of the mechanisms of action of GDM intervention on mother and baby. GDM, gestational diabetes mellitus.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. International Diabetes Federation. IDF diabetes atlas. 8th edition Brussels: International Diabetes Federation; 2017.

Cited by

See all 79

Metadata

Authors
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E.
Affiliations
University of Cambridge (GB)
Venue
PLoS Medicine
Published
2020-05-22
Volume
17
Issue
5
Pages
e1003126
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W3027421343
Cited by
73
References
78
Citations by year
2026: 3 · 2025: 12 · 2024: 11 · 2023: 18 · 2022: 12 · 2021: 15 · 2020: 2
FWCI
1.38
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • British Heart Foundation (RG/17/12/33167)
  • Medical Research Council (MC_ UU_12012/4)
  • Isaac Newton Trust/Wellcome Trust ISSF/ University of Cambridge Joint Research Grant
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
Keywords
gestational diabetes mellitus, metformin, glibenclamide, insulin therapy, neonatal anthropometry, birth weight, macrosomia, fetal growth, child growth, maternal glycaemic control, placental transfer
MeSH terms
Anthropometry, Birth Weight, Blood Glucose, Female, Fetal Macrosomia, Glyburide, Humans, Hypoglycemic Agents, Infant, Newborn, Pregnancy, Diabetes, Gestational

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.